Vaccine Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Enterococcal Infection
Patent issued for Enterococcus antigens and vaccines
September 8th, 2004
Nabi Biopharmaceuticals (NABI) has been granted U.S. Patent No. 6,756,361 entitled "Enterococcus Antigens and Vaccines" by the U.S. Patent and Trademark Office. The patent covers the composition of multiple Enterococcus faecalis and Enterococcus faecium capsular polysaccharide antigens (Enterococcus antigens), which have been shown to induce serotype-specific protective immunity against multi-drug resistant enterococcal species. The indicated polysaccharides cover more than 85% of all enterococcal infection isolates from hospitals across the United States. The patent also covers the use of these antigens as vaccines, and methods for...
Source: Vaccine Weekly (2004-09-08)
|
